Navigation Links
Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments
Date:11/9/2010

ially successful or will effectively enhance our businesses or their market value, or that the MedPodium product line can be successfully broadened to include additional healthy lifestyle opportunities, or that we can effectively promote commercialization of our products on our own or through third parties; that improvements in the formulation or use of Generx will be commercially practicable, or that Generx could be successfully advanced as a therapeutic in developing markets or that the results of studies in such markets could be used to advance or broaden the commercialization of Generx in the U.S. or other markets; that Nitric Oxide or other technologies we investigate can be used to effectively expand or improve our product portfolio; that our product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive; that our clinical study programs can be conducted and completed in an efficient and successful manner; that we can develop a DNA-based orthobiologics product portfolio; that the FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; or that third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our depen
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Cardium to Present at the LifeTech Capital Miami Medical Investors Conference
2. Cardium Gains Exclusive Access to Novel Polymer-Based Nitric Oxide Technology for Expansion of Wound Healing Product Portfolio
3. Cardium to Present at 10th Annual Biotech in Europe Investor Forum
4. Cardium Regains Listing Compliance With NYSE Amex
5. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference
6. Cardiums Exchange Listing Compliance Plan Accepted by NYSE AMEX
7. Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
8. Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds
9. Cardium Completes $6.0 Million Registered Direct Offering
10. Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
11. Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... ... July 03, 2015 , ... ... Fortune 500 companies and professional service industries alike-- typically known for its consummate ... laugh, honor a good cause and break from their day jobs. , "Our ...
(Date:7/3/2015)... , July 3, 2015 ... for Open Innovation in Science", som finner ... Søknadene sendes på nett, på  http://www.openinnovationinscience.at , ... 2015.  De to største utfordringene ... å undersøke nye forskningsspørsmål og kompleksiteten av ...
(Date:7/2/2015)... (PRWEB) , ... July 03, 2015 , ... Cuvettes have been used in countless labs ... catalog to find the cuvette they needed. As expected, this was a daunting and ... the wrong part because they were not able to navigate the complex catalog structure. , ...
(Date:7/2/2015)... 2015 Amici Procurement Migrates to ... Amici Procurement has chosen Microsoft Cloud Solution Provider ... Office 365.      (Logo: http://photos.prnewswire.com/prnh/20121126/579634) , ... companies in the bio-tech sector with a unique procurement ... cycle to help them obtain best value. Its IT ...
Breaking Biology Technology:The Alexander Group Declares Their Independence with a Bit of Levity 2Lansering av verdens første Open Innovation-program for utdanning av forskere 2Lansering av verdens første Open Innovation-program for utdanning av forskere 3New Cuvette E-Commerce Website Launched by FireflySci 2Biotech Procurement Company Moves to Office 365 with iomart 2
... BioSpace, the leading online,source of life science ... this morning the ninth edition of the ... ), (Logo: http://www.newscom.com/cgi-bin/prnh/20040907/CLTU006LOGO ), ... features promotional and,functional web components to work ...
... Transgene,(Euronext Paris: FR0005175080) announces promising preliminary data from,the ... as an adjunct to first line chemotherapy in ... This on-going trial is a randomized, open label ... TG4010 in combination with cisplatin and,gemcitabine compared to ...
... services and, product revenues increased 16% and ... year and $24.6 million for the fourth quarter, ... ),a biomaterials, medical device and tissue processing company, announced,today ... $93.7 million compared to $81.1 million in 2006, an ...
Cached Biology Technology:BioSpace and the Massachusetts Biotechnology Council Launch 2008 Genetown(TM) Hotbed Campaign 2Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer 2Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer 3CryoLife Announces Record Preservation Services and Product Revenues for 2007 2CryoLife Announces Record Preservation Services and Product Revenues for 2007 3CryoLife Announces Record Preservation Services and Product Revenues for 2007 4
(Date:6/30/2015)... HATFIELD, Pa. , June 30, 2015 ... joined the company as CEO to help further develop ... a wealth of partnering experience, having spent much of ... companies including Therakine, Amgen, Baxter Bioscience, and Johnson & ... a focus on Technology and Biotech Corporate Finance. He ...
(Date:6/25/2015)... N.J. , June 25, 2015  TAKE Solutions ... a patent by the United States Patent and Trademark ... Standardization". This process leverages TAKE Solutions, Clinical Accelerators to ... over 50% (when compared to standardization without the accelerators), ... At the heart of ...
(Date:6/24/2015)... Switzerland , June 24, 2015 ... partnership with emerging biometric password solution one face ... one face in, entering ... a ground-breaking and affordable multifactor-authentication biometric answer to ... recognition technology, provided in partnership with KeyLemon, one ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... member at the Wyss Institute for Biologically Inspired Engineering at ... Bioengineering at the Harvard School of Engineering and Applied Sciences, ... the National Academies, which is one of the highest honors ... The IOM is an organization with more than 1,900 members ...
... near future, solar panels will not only be more efficient ... to research by Nanyang Technological University (NTU) scientists. This ... is about five times cheaper than current thin-film solar cells, ... known to be a remarkable solar cell material as it ...
... University of Liverpool has found that greater consideration ... infectious disease model would improve its effectiveness/usefulness and ... central role in planning for outbreaks of human ... progress and guiding and informing policy responses. ...
Cached Biology News:Wyss Institute core faculty member elected to the Institute of Medicine of the National Academies 2NTU scientists make breakthrough solar technology 2NTU scientists make breakthrough solar technology 3Study explores the role of uncertainty in infectious disease modelling 2
Thermo Forma provides an array of accessory Racks for the Cryo/CryoPlus 16" Diameter storage system. To maximise inventory capacity a Jumbo Arrowhead configuration is recommended. You may choose betw...
...
The Holten mini vertical flow workbench provides a particle-free environment for sample protection against airborne contaminants....
...
Biology Products: